Table 4.

Predictors of Maternal Complete Response to Study Vaccinations (Univariate Analyses)

Characteristic	Dose 1			Dose 2
	No.a	OR (95% CI)	P Value	No.a	OR (95% CI)	P Value
Age	119	1.062 (.992–1.136)b	.09	107	1.056 (.982–1.136)b	.1
Black race	112	.989 (.449–2.175)	1.0	100	1.364 (.589–3.158)	.5
Hispanic ethnicity	115	1.546 (.691–3.455)	.3	103	1.268 (.533–3.020)	.6
Nadir CD4 percentage	113	1.071 (1.031–1.113)c	<.001	102	1.054 (1.014–1.096)c	.01
Nadir CD4 count	113	1.002 (1.000–1.004)d	.02	102	1.003 (1.001–1.005)d	.01
P1061s CD4 percentage	119	1.068 (1.028–1.109)c	.001	107	1.043 (1.004–1.083)c	.03
P1061s CD4 count	116	1.002 (1.000–1.004)d	.02	105	1.002 (1.000–1.004)d	.03
P1061s CD8 percentage	119	.963 (.931–.996)c	.03	107	.976 (.941–1.011)c	.2
P1061s CD8 count	109	.999 (.998–1.000)d	.2	98	.999 (.998–1.001)d	.4
P1061s CD19 percentage	108	.983 (.912–1.059)c	.7	98	.983 (.909–1.063)c	.7
P1061s CD19 count	97	.999 (.996–1.002)d	.6	88	.999 (.996–1.002)d	.6
P1061s HIV viral load <400 copies/mL	119	1.253 (.570–2.759)	.6	107	1.047 (.446–2.459)	.9
HAART	119	.596 (.111–3.205)	.5	107	.743 (.137–4.028)	.7
Gestational age at entry	119	1.017 (.954–1.083)e	.6	107	1.010 (.943–1.080)e	.8
Seasonal influenza vaccination prior to entry	119	.907 (.403–2.039)	.8	107	.945 (.394–2.268)	.9
pH1N1 HAI titer ≥40 at entry	119	.974 (.396–2.397)	1.0	107	.616 (.240–1.581)	.3
pH1N1 log10 HAI titer at entry	119	1.054 (.396–2.803)f	.9	107	.695 (.249–1.944)f	.5

Complete responses after dose 2 were based on antibody titers measured at the 10 days post–dose 2 timepoint.

Abbreviations: CI, confidence interval; HAART, highly active antiretroviral therapy; HAI, hemagglutination inhibition; OR, odds ratio.

^a No. of participants with available data.

^b Odds ratio for every year increase.

^c Odds ratio for every 1% increase.

^d Odds ratio for every cell/mm³ increase.

^e Odds ratio for every week increase.

^f Odds ratio for every log₁₀ increase in titer.